Merck & Co., Inc.
NYSE:MRKDrug Manufacturers - General
-$1.32 today
- Market cap
- $339.66B
- Beta
- 0.22
- P/E (TTM)
- 31.6
- EPS (TTM)
- $3.61
- Dividend yield
- 2.94%
Volume 9.69M
Average 11.85M
MRK Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Merck & Co., Inc.NYSE: MRK
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q2 FY2026 capital expenditures of $893M (cash outflow) rose 16.9% year over year, ahead of the +2.4% change in trailing-twelve-month capital expenditures. Sequentially, it fell 9.9% from the prior quarter. Over 3 fiscal years it compounded at -2.1% a year.
Context
- Capital expenditures amounted to 6.3% of revenue in FY2025, up 1.1 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +16.9% holds above the trailing-twelve-month pace of +2.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (4.11B) USD
- Year-over-year change
- -21.9%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.11B) | -21.9% |
| FY2024 | 2024-12-31 | (3.37B) | +12.7% |
| FY2023 | 2023-12-31 | (3.86B) | +12.0% |
| FY2022 | 2022-12-31 | (4.39B) | +1.3% |
| FY2021 | 2021-12-31 | (4.45B) | — |
Capital Expenditures vs competitors
How MRK compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +2.4% is the 4th highest of 9, against a peer median of -19.5%.
- Capital expenditures amounts to 5.9% of revenue for MRK, versus a peer median of 5.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $8.03B USD | -26.9% | +38.0% | 10.1% | |
| LTM Sep 2026 | $5.57B USD | +8.6% | +6.4% | 5.6% | |
| LTM Sep 2026 | $4.01B USD | -28.0% | +31.9% | 6.5% | |
| LTM Jun 2026 | $3.9B USD | +2.4% | -2.1% | 5.9% | |
| LTM Jun 2026 | $2.57B USD | -35.5% | -11.4% | 4.6% | |
| LTM Jun 2026 | €2.52B EUR | — | -1.8% | 5.2% | |
| LTM Jun 2026 | $2.42B USD | -12.1% | -6.7% | 3.8% | |
| LTM Jun 2026 | $2.3B USD | +63.6% | +25.7% | 6.0% | |
| LTM Jun 2026 | $1.3B USD | +24.2% | +20.4% | 2.0% | |
| LTM Jun 2026 | $352M USD | -29.5% | -8.2% | 1.2% | |
| Peer median (excluding MRK) | — | -19.5% | +6.4% | 5.2% | |
Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 12.36B | 14.53B | 365M | 17.13B | 18.25B |
| Depreciation & Amortization | 3.21B | 3.91B | 3.87B | 4.5B | 5.84B |
| Deferred Income Tax | 187M | (1.57B) | (1.9B) | (1.25B) | (1.67B) |
| Stock-Based Compensation | 479M | 541M | 645M | 761M | 0 |
| Change in Working Capital | (3.84B) | (2.78B) | (2.21B) | (3.67B) | (6.98B) |
| Accounts Receivables | (2.03B) | (644M) | (1.15B) | (244M) | (1.09B) |
| Inventory | (674M) | (161M) | (816M) | (835M) | (1.18B) |
| Accounts Payables | 405M | (289M) | (380M) | 182M | 110M |
| Other Working Capital | (1.54B) | (1.69B) | 139M | (2.77B) | (4.82B) |
| Other Non-Cash Items | 1.71B | 4.47B | 12.23B | 3.99B | 1.03B |
| Operating Cash Flow | 14.11B | 19.1B | 13.01B | 21.47B | 16.47B |
| Capital Expenditures | (4.45B) | (4.39B) | (3.86B) | (3.37B) | (4.11B) |
| Acquisitions (Net) | (12.91B) | (121M) | (12.03B) | (4.09B) | (10.04B) |
| Purchases of Investments | (1M) | (1.2B) | (955M) | (519M) | (1.21B) |
| Sales of Investments | 1.03B | 721M | 1.66B | 377M | 1.68B |
| Other Investing Activities | (225M) | 32M | 1.11B | (127M) | (58M) |
| Investing Cash Flow | (16.56B) | (4.96B) | (14.08B) | (7.73B) | (13.74B) |
| Debt Repayment | 1.63B | (2.25B) | 4.18B | 2.31B | 11.38B |
| Common Stock Issued | 0 | 384M | 0 | 0 | 92M |
| Common Stock Repurchased | (840M) | 0 | (1.35B) | (1.31B) | (5.08B) |
| Dividends Paid | (6.61B) | (7.01B) | (7.45B) | (7.84B) | (8.18B) |
| Other Financing Activities | 8.41B | (240M) | (203M) | (195M) | (131M) |
| Financing Cash Flow | 2.59B | (9.12B) | (4.81B) | (7.03B) | (1.92B) |
| Effect of Forex Changes | (133M) | (410M) | 23M | (293M) | 563M |
| Net Change in Cash | 14M | 4.61B | (5.86B) | 6.41B | 1.37B |
| Free Cash Flow | 9.66B | 14.71B | 9.14B | 18.1B | 12.36B |
Merck & Co., Inc.
NYSE:MRK
Intrinsic Alpha fair value
Locked
Current Price
$137.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.